Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
1701-1720 of 2,251 trials

Chronic Infection in Hip and Knee Implants: 68Ga PET/CT Study

We are investigating whether a new imaging technique can accurately diagnose chronic infections in artificial hip and knee joints. This study compares its effectiveness to other existing diagnostic methods.

Prosthetic Joint Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOrthopedics and TraumatologyOtolaryngology

Triple-Negative Breast Cancer: Optimizing Pembrolizumab Use

We are studying whether observing patients after surgery is as effective as continuing pembrolizumab treatment for those who responded well to initial therapy. This trial also looks at safety, quality of life, and fertility impacts.

Early Triple-Negative Breast Cancer (TNBC)6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Antibiotics in Cerebrospinal Fluid: A Study in Children

We are examining how well antibiotics work in the cerebrospinal fluid of children with an external ventricular drain. This research aims to improve treatment for infections in these patients.

Patients with External Ventricular Drain>2 yearsSafety phase (I)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

HIV Treatment: Comparing DOR/3TC and DTG/3TC

We are studying whether a new two-drug regimen can maintain viral suppression in people living with HIV who are currently stable on a three-drug treatment. This trial will also assess various health outcomes and side effects over time.

HIV Disease>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious Diseases

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Vemurafenib for BRAF Positive Juvenile Histiocytosis

We are studying the safety and effectiveness of vemurafenib in children with BRAF mutation-resistant histiocytosis. This trial aims to find the best dosage and treatment duration for these young patients.

Histiocytic Cell Proliferation>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Atenativ for Congenital Antithrombin Deficiency During Surgery

We are studying how Atenativ may help patients with congenital antithrombin deficiency during surgical procedures or childbirth. The trial looks at its safety, effectiveness, and how the body processes the medication.

Congenital Antithrombin Deficiency>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsHematologyInternal Medicine

Oxybutynin for Boys with Posterior Urethral Valves

We are studying whether early treatment with oxybutynin improves bladder function in boys after surgery for posterior urethral valves. The trial also looks at the safety of the medication and its effects on urinary tract infections.

Urethral Posterior Valve>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPediatricsUrology

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Brain Metastases Detection: PET-DOPA Imaging Study

We are studying a new imaging method to detect untreated brain metastases in patients with lung, breast, or melanoma cancer. This research aims to improve how we identify and understand these tumors.

Brain Metastases from Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics

Clindamycin for Infections: Impact of Rifampicin and Obesity

We are studying how body weight and the antibiotic rifampicin affect the effectiveness of clindamycin in treating infections. This research may help improve treatment strategies for patients with varying body types.

Hidradenitis SuppurativaProsthetic Joint InfectionsFracture Related Infections≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Biliary Tract Cancer: Ivonescimab vs. FOLFOX

We are testing a new treatment, ivonescimab, against standard chemotherapy for patients with advanced biliary tract cancer. The goal is to see if it helps patients live longer and feel better.

Advanced Biliary Tract Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicinePulmonology

Histiocytosis: Fludeoxyglucose (18F-FDG) Imaging Study

We are examining how fludeoxyglucose (18F-FDG) in PET/CT scans can help monitor juvenile patients with histiocytosis. The study will assess its safety and potential benefits for those with specific mutations.

Erdheim-Chester DiseaseLangerhans Cell SarcomaRosai-Dorfman Syndrome>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesHematologyOtolaryngology